



Catalyst Pharmaceuticals, Inc.  
Investor Relations Department  
355 Alhambra Circle  
Suite 1250  
Coral Gables, FL 33134  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: CPRX <sup>1</sup>

Last Trade:	4.10
Trade Time:	4:00 PM ET 12/14/17
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.01 - 4.51
Volume	N/A
Market Cap. (\$M)	420.127
Shares Out (M)	102.470

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 11/30/17 [Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Public Offering](#)
- 11/28/17 [Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock](#)
- 11/27/17 [Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock](#)
- 11/27/17 [Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome](#)
- 11/21/17 [Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy \(SMA\)](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

- 03/15/17 [Annual Report \(10-K\)](#)
- 04/14/17 [Definitive Proxy Statement](#)
- 11/08/17 [Quarterly Report \(10-Q\)](#)
- 08/09/17 [Quarterly Report \(10-Q\)](#)
- 05/10/17 [Quarterly Report \(10-Q\)](#)